25 results about "CD30" patented technology

The present invention provides a non-human animal expressing human or chimeric (e.g., humanized) CD30L and / or CD30 proteins and methods of use thereof.

The invention relates to a gene-edited cytotoxic cell comprising a chimeric antigen receptor (CAR) that binds CD30, for use in the treatment of an infection, in which infected cells express CD30. In embodiments, the treatment comprises the cytotoxic cell binding to a human target cell, which is infected with a chronic inflammatory virus and expresses CD30. In embodiments, the treatment comprises cytotoxic activity against a reservoir of infected human CD30-expressing target cells in a subject with a chronic viral infection with associated pathologies, immune dysregulations and autoimmune diseases. Corresponding medical uses and methods of treatment are encompassed by the present invention. In another aspect, the invention relates to the CD30-CAR-expressing gene-edited cytotoxic cell as described herein. In other aspects, the invention relates to the CD30-CAR nucleic acid construct and the CAR polypeptide as described herein.

The present disclosure relates to expanding and production of gamma delta (γδ) T cells, e.g., Vδ1+ γδ T cells. In particular, the present disclosure provides improved methods and processes for activating and expanding γδ T cells (e.g., Vδ1+ γδ T cells) using combined CD3 and CD30 agonists and cytokines.

The invention relates to a humanized CD30 antibody, a CD30 CAR-T cell and application of the humanized CD30 antibody and the CD30 CAR-T cell. Specifically, the present invention provides a humanized antibody targeting CD30, a chimeric antigen receptor (CAR) fusion protein comprising a humanized antigen binding domain targeting CD30, and an engineered immune cell (e.g., a CAR-T cell) expressing the CAR fusion protein. The CAR-T cell disclosed by the invention has relatively high affinity and biological activity, relatively good amplification performance and relatively good in-vitro and in-vivo anti-tumor effects.

The invention relates to an anti-CD30 nano antibody as well as a preparation method and application thereof. The anti-CD30 nano antibody is obtained through a phage display technology. The method disclosed by the invention is simple and quick to operate; and a mammalian cell expression system induces high-efficiency expression of the antibody, and the activity of the antibody is closer to that of a natural antibody. The anti-CD30 nano antibody which is specifically combined with the Human CD30 is obtained through enzyme-linked immuno sorbent assay (ELISA) and FACS detection.

This invention provides a method for screening peptides that specifically target T cells, comprising providing T cells having a subset selected from CD1, CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, CD150, CD152 (CTLA-4), CD153, CD154 (CD40L) The T cells are labeled with at least one of the following surface antigen markers: CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, LAG3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6, and CCR7. The T cells are then contacted with a peptide display library, and target peptides that specifically bind to the T cells are screened therefrom.

Provided is a method for screening polypeptides that specifically target T cells, comprising: providing T cells having a surface antigen marker selected from at least one of CD1, CD2, CD3, CD4, CD5, CD7, CD8, CD16, CD25, CD26, CD27, CD28, CD30, CD38, CD39, CD40L, CD44, CD45, CD62L, CD69, CD73, CD80, CD83, CD86, CD95, CD103, CD119, CD126, CD150, CD152 (CTLA-4), CD153, CD154 (CD40L), CD161, CD183, CD223, CD254, CD275, CD45RA, CXCR3, CXCR5, FasL, IL18R1, CTLA-4, OX40, GITR, LAG3, ICOS, PD-1, leu-12, TCR, TLR1, TLR2, TLR3, TLR4, TLR6, NKG2D, CCR, CCR1, CCR2, CCR4, CCR6, and CCR7; and contacting the T cells with a polypeptide display library, and screening therefrom target polypeptides that specifically bind to the T cells.

The invention relates to the field of biological medicine, and provides a medicine composition for treating tumors and application. The pharmaceutical composition comprises a first active component and a second active component, the first active component comprises a CD30 targeted drug and a pharmaceutically acceptable small molecule compound / salt thereof, the CD30 targeted drug comprises at least one of CD30 CAR-T cells and vibtuximab, and the second active component comprises a pharmaceutically acceptable small molecule compound / salt thereof and a pharmaceutically acceptable small molecule compound / salt thereof, and the CD30 targeted drug comprises at least one of CD30 CAR-T cells and vibtuximab. The second active component comprises a glycosphingolipid synthesis inhibitor and a pharmaceutically acceptable small molecule compound / salt thereof, the glycosphingolipid synthesis inhibitor comprises at least one of eaglukast and meglumine, and the research finds that the combination of the CD30 targeted drug and the glycosphingolipid synthesis inhibitor has a synergistic effect. The invention provides an effective drug combination strategy for tumor treatment, and has a good application prospect in tumor treatment drug selection.

The present disclosure relates to a method of expanding or producing CD56 + / CD3-cells, said method comprising contacting said CD56 + / CD3-cells with an NKp46 agonist and / or a CD30 agonist.

The present invention relates to pharmaceutical compositions comprising multispecific antibodies capable of binding to CD3 and CD30. The invention further provides the use of the pharmaceutical composition for therapeutic and diagnostic procedures, in particular cancer therapy.

The present invention relates to a pharmaceutical composition comprising a multispecific antibody capable of binding to CD3 and CD30. The present invention further provides the use of the pharmaceutical composition for therapeutic and diagnostic procedures, particularly for the treatment of cancer.

The invention relates to a bispecific chimeric antigen receptor (CAR) and application thereof, the CAR comprises a binding domain, and the binding domain comprises a CD30 binding domain and a CD20 binding domain. The invention further relates to an immune cell for expressing the chimeric antigen receptor and application of the immune cell.

The present invention relates, in particular, to T cells expressing a polypeptide-containing chimeric CD95 receptor, wherein the polypeptide comprises at least one CD95-derived polypeptide region having at least 60% sequence identity with a polypeptide domain, polypeptide region, or polypeptide motif of the human CD95 wild-type receptor, the human CD95 polypeptide region comprises a CD95 extracellular ligand-binding domain, and further comprises at least one non-CD95-derived costimulatory cytoplasmic polypeptide domain, region, or motif of tumor necrosis factor receptor superfamily proteins, including CD40, CD40L, CD27, HVEM, GITR, CD30, OX40, and / or LTBR, ​​immunoglobulin superfamily (IgSF) proteins, Toll-like receptors, and / or IL6 receptor family proteins, and the T cells further express the modified T cell receptor.

The invention relates to the technical field of molecular biology and genetic engineering, and discloses sgRNA targeting a chicken CD30 gene and a combination and application thereof. The sgRNA and the sgRNA combination provided by the invention perform targeted knockout on the seventh exon region (transmembrane region) of the chicken CD30 gene, and the sgRNA knockout target of the chicken CD30 is transfected into a chicken fibroblast line DF-1 to prepare the CD30 knockout DF-1 cell, namely the CD30 / -DF-1 cell, and compared with a control group cell through detection, the CD30 expression quantity in the CD30 / -DF-1 cell is extremely low, and the result shows that the CD30 is successfully edited. The establishment of the CD30- / -DF-1 cell line provides an experimental material for deeply researching the functions of CD30.

The application discloses application of a reagent for detecting pSTAT3 expression level in identification of PTCL-NOS and ALK-ALCL, relates to the technical field of biological medicine, and finds that detection of the phosphorylation level of STAT3-S727 of a sample can be well used for identification of PTCL-NOS and ALK-ALCL expressing CD30, the identification process is simple and rapid, and is high in specificity and sensitivity, thereby providing a new effective approach for differential diagnosis of PTCL-NOS and ALK-ALCL expressing CD30.

This invention provides a dual-target engineered immune cell capable of simultaneously targeting CD30 and BCMA to reduce tumor cell escape and recurrence rate. Specifically, this invention provides an engineered immune cell comprising a chimeric antigen receptor targeting BCMA and CD30, wherein the chimeric antigen receptor comprises: (1) an antigen-binding region comprising an antibody targeting BCMA and an antibody targeting CD30; (2) a transmembrane domain; and (3) a primary signal transduction domain. This invention also provides an engineered immune cell comprising: (1) a first chimeric antigen receptor targeting BCMA, comprising an antibody targeting BCMA, a transmembrane domain, and a primary signal transduction domain; and (2) a second chimeric antigen receptor targeting CD30, comprising an antibody targeting CD30, a transmembrane domain, and a primary signal transduction domain.

Development of biomarkers for the diagnosis of the condition, severity, disease type of severe drug eruptions such as drug hypersensitivity syndrome and Stevens-Johnson syndrome / toxic epidermal necrolysis. A method for detecting severe drug eruptions, comprising the steps of: measuring the expression of at least one protein selected from the group consisting of a stratified protein, TNF receptor superfamily member 8 (CD30 / TNFRSF8), interleukin-1 receptor antagonist (IL-1Ra), and TNF receptor superfamily member 6B (DcR3 / TNFRSF6B) in a sample derived from a subject.

Disclosed herein are a novel antibody and an antigen binding fragment thereof that targets CD30 to treat cancer, a chimeric antigen receptor, and a use thereof. The antibody, which binds specifically to CD30 that is highly expressed in cancer cells (specifically blood cancer), is very low in sequence homology with the CDR sequences of conventional CD30 targeting antibodies and thus has a unique sequence. Cells that express the chimeric antigen receptor including the anti-CD30 antibody or the antigen binding fragment responds to CD30-expressing positive cells to induce immune cell activity, thus finding advantageous applications as a CAR-immune cell product.

In particular, the present invention relates to a T cell expressing a chimeric CD95 receptor comprising a polypeptide wherein the polypeptide comprises at least one CD95-derived polypeptide region having at least 60% sequence identity to a polypeptide domain, a polypeptide region or a polypeptide motif of a human CD95 wild type receptor wherein the human CD95 polypeptide region comprises a CD95 extracellular ligand binding domain; further, wherein the polypeptide comprises at least one non-CD95-derived co-stimulatory cytoplasmic polypeptide domain, region or motif of a tumor necrosis factor receptor superfamily protein, an immunoglobulin superfamily (IgSF) protein, a Toll-like receptor and / or an IL6 receptor family protein, the tumor necrosis factor receptor superfamily protein comprising CD40, CD40L, CD27, HVEM, GITR, CD30, OX40 and / or LTBR; wherein the T cell also expresses an engineered T cell receptor. The invention also relates to a vector comprising a nucleic acid encoding a CD95 receptor and an engineered T cell receptor, as well as a kit for preparing the T cell of the invention, and a pharmaceutical composition comprising said T cell. The invention also relates to a method of preparing T cells for immunotherapy and a method of treating a patient suffering from a disease comprising administering the pharmaceutical composition.

Aspects of the present disclosure include improvements to chimeric antigen receptor (CAR) constructs, CAR comprising immune cells, as well as methods for making such constructs and / or cells and methods for their use in treatment of disease (e.g., cancer). Disclosed are immune cells comprising CARs comprising CD30-derived hinge and / or transmembrane and methods for use of such cells in treatment of malignancies (e.g., B-cell malignancies). Also disclosed are polynucleotides encoding a CAR comprising CD30-derived hinge and / or transmembrane domains, as well as cells comprising such polynucleotides and pharmaceutical compositions comprising such cell

The present application provides an anti-human CD153 monoclonal antibody, or a binding fragment thereof, that specifically binds to human CD153 and inhibits the intermolecular interaction between human CD153 and CD30. The present application further provides: a chimeric antigen receptor comprising an extracellular antigen binding domain, a transmembrane domain and an intracellular signal transduction domain wherein the extracellular antigen binding domain comprises a single-chain antibody having a heavy chain hypervariable region and a light chain hypervariable region which are the same as those of the monoclonal antibody of the present application; the invention also discloses a CAR-T cell for expressing the chimeric antigen receptor. The monoclonal antibody, the binding fragment of the monoclonal antibody and the CAR-T cell can be used for treating or preventing diseases related to CD153, such as multiple sclerosis. The invention provides the anti-human CD153 monoclonal antibody or the binding fragment of the anti-human CD153 monoclonal antibody which specifically binds to human CD153 and inhibits intermolecular interaction between the human CD153 and CD30. The present application further provides: a chimeric antigen receptor comprising an extracellular antigen binding domain, a transmembrane domain and an intracellular signal transduction domain wherein the extracellular antigen binding domain comprises a single-chain antibody having a heavy chain hypervariable region and a light chain hypervariable region which are the same as those of the monoclonal antibody of the present application; the invention also discloses a CAR-T cell for expressing the chimeric antigen receptor. The monoclonal antibody, the binding fragment thereof and the CAR-T cell can be used for treating or preventing diseases related to CD153, such as multiple sclerosis.

The invention discloses a novel antibody for targeting CD30 to treat cancer, an antigen binding fragment of the antibody, a chimeric antigen receptor and application of the antibody. The antibody of the present invention is an antibody specifically binding to CD30 highly expressed in cancer cells (particularly leukemia), which has extremely low homology compared to the CDR sequence of a conventional CD30 targeting antibody, and thus has a unique sequence. A cell expressing a chimeric antigen receptor comprising the anti-CD30 antibody or antigen-binding fragment of the present invention induces immune cell activity in response to a positive cell line expressing CD30, and thus can be advantageously used as a CAR immune cell therapeutic agent.

The invention relates to a gene-edited cytotoxic cell comprising a chimeric antigen receptor (CAR) that binds CD30, for use in the treatment of an infection, in which infected cells express CD30. In embodiments, the treatment comprises the cytotoxic cell binding to a human target cell, which is infected with a chronic inflammatory virus and expresses CD30. In embodiments, the treatment comprises cytotoxic activity against a reservoir of infected human CD30-expressing target cells in a subject with a chronic viral infection with associated pathologies, immune dysregulations and autoimmune diseases. Corresponding medical uses and methods of treatment are encompassed by the present invention. In another aspect, the invention relates to the CD30-CAR-expressing gene-edited cytotoxic cell as described herein. In other aspects, the invention relates to the CD30-CAR nucleic acid construct and the CAR polypeptide as described herein.

The invention provides an anti-CD30 single-domain antibody and an application of the anti-CD30 single-domain antibody. The anti-CD30 single-domain antibody disclosed by the invention can be combined with CD30 with high affinity, is small in molecular weight and low in immunogenicity, and has an application prospect in detection of CD30 and treatment of related diseases.